Inozyme Pharma Inc (INZY)
4.82
+0.13
(+2.77%)
USD |
NASDAQ |
May 31, 16:00
4.82
0.00 (0.00%)
After-Hours: 20:00
Inozyme Pharma Enterprise Value: 177.02M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 177.02M |
| May 30, 2024 | 168.98M |
| May 29, 2024 | 157.85M |
| May 28, 2024 | 151.04M |
| May 24, 2024 | 161.56M |
| May 23, 2024 | 160.94M |
| May 22, 2024 | 168.36M |
| May 21, 2024 | 169.60M |
| May 20, 2024 | 171.46M |
| May 17, 2024 | 163.41M |
| May 16, 2024 | 171.46M |
| May 15, 2024 | 167.74M |
| May 14, 2024 | 165.27M |
| May 13, 2024 | 157.85M |
| May 10, 2024 | 159.70M |
| May 09, 2024 | 166.51M |
| May 08, 2024 | 165.89M |
| May 07, 2024 | 163.41M |
| May 06, 2024 | 180.73M |
| May 03, 2024 | 172.07M |
| May 02, 2024 | 166.51M |
| May 01, 2024 | 164.03M |
| April 30, 2024 | 151.66M |
| April 29, 2024 | 152.28M |
| April 26, 2024 | 153.52M |
| Date | Value |
|---|---|
| April 25, 2024 | 146.71M |
| April 24, 2024 | 151.04M |
| April 23, 2024 | 151.04M |
| April 22, 2024 | 150.42M |
| April 19, 2024 | 157.67M |
| April 18, 2024 | 162.00M |
| April 17, 2024 | 166.33M |
| April 16, 2024 | 178.69M |
| April 15, 2024 | 170.03M |
| April 12, 2024 | 196.62M |
| April 11, 2024 | 201.56M |
| April 10, 2024 | 202.80M |
| April 09, 2024 | 217.63M |
| April 08, 2024 | 241.74M |
| April 05, 2024 | 275.12M |
| April 04, 2024 | 280.07M |
| April 03, 2024 | 322.10M |
| April 02, 2024 | 307.27M |
| April 01, 2024 | 330.76M |
| March 28, 2024 | 329.35M |
| March 27, 2024 | 312.68M |
| March 26, 2024 | 274.99M |
| March 25, 2024 | 241.02M |
| March 22, 2024 | 214.46M |
| March 21, 2024 | 218.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-94.96M
Minimum
Dec 30 2022
641.75M
Maximum
Sep 01 2020
158.31M
Average
143.63M
Median
Enterprise Value Benchmarks
| Xeris Biopharma Holdings Inc | 475.90M |
| Kodiak Sciences Inc | -78.86M |
| Phathom Pharmaceuticals Inc | 378.20M |
| Athira Pharma Inc | -21.67M |
| Disc Medicine Inc | 495.70M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.35M |
| Total Expenses (Quarterly) | 24.34M |
| EPS Diluted (Quarterly) | -0.38 |
| Earnings Yield | -28.42% |